Following yesterday's news that BENLYSTA met its primary endpoint in a second Phase 3 trial, and the resulting 35% spike ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE